Robert W. Baird Has Lowered Expectations for MiNK Therapeutics (NASDAQ:INKT) Stock Price

Posted by Stephan Jacobs on Nov 15th, 2024

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) had its target price reduced by analysts at Robert W. Baird from $8.00 to $4.00 in a report released on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price points to a potential upside of 433.33% from the company’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of MiNK Therapeutics in a research note on Wednesday, October 9th.

Check Out Our Latest Research Report on INKT

MiNK Therapeutics Stock Performance

NASDAQ:INKT opened at $0.75 on Friday. MiNK Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $1.90. The firm has a market cap of $29.66 million, a PE ratio of -1.53 and a beta of 0.05. The business has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.85.

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. Research analysts predict that MiNK Therapeutics will post -0.33 EPS for the current year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC lifted its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) by 21.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

(Get Free Report)

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.